A novel cancer vaccine utilizing the PROTEXI platform is designed to harness the immune memory established after COVID-19 infection or vaccination to bolster the immune system's ability to combat tumors. This innovative approach has been developed by a team of researchers from Case Western Reserve University and Celloram.
So, how does this vaccine function? Cancer cells often mimic healthy tissues, making it challenging for T cells to identify them as harmful. The PROTEXI platform aims to improve the immune system's capacity to target these tumors effectively. Each vaccine is tailored to the individual patient, incorporating a dendritic cell—known as the immune system's "scout"—that is infused with both tumor-specific antigens and a segment of the spike protein from the SARS-CoV-2 virus. This familiar viral marker triggers helper T cells, which not only amplify the immune response but also steer it towards the tumor antigens presented by the same dendritic cell.
In preclinical trials involving mice with melanoma and breast cancer, the vaccine demonstrated a significant reduction in tumor growth and an increase in survival rates. Notably, some of the mice that survived were later exposed again to melanoma cells, and the formation of new tumors was largely inhibited, indicating the development of anti-tumor immune memory. Additionally, trials in mice that possessed components of the human immune system from a donor who had been vaccinated against COVID-19 showed that the vaccine improved T-cell responses and decreased tumor burden. The researchers are optimistic about initiating human clinical trials in the near future.
Informational material. 18+.
